DOSING &
ADMINISTRATION
Grace
Person with PH1*

*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.

OXLUMO® (lumasiran) is a subcutaneous injection dosed by weight1

Administered via subcutaneous injection by a healthcare professional1

Image

3 monthly starting doses aim to reduce oxalate levels1

Image

Ongoing dosing beginning one month after the last
starting dose aims to sustain the reduction1

Ongoing dosing of OXLUMO is quarterly or monthly

With a dosing regimen designed for PH1 management, OXLUMO is administered monthly for the first 4 months of treatment. After month 4, dosing is available quarterly for patients who weigh ≥10 kg or monthly for patients who weigh <10 kg.

3 starting doses: 3 mg/kg administered monthly

3mg/kg dose

Start

3mg/kg dose

Month 1

3mg/kg dose

Month 2

Ongoing dosing: 3 mg/kg administered quarterly beginning one month after the last starting dose

3mg/kg dose

Month 3

No dose

Month 4

No dose

Month 5

3mg/kg dose

Month 6

Ongoing quarterly dosing continues past month 6

Download the Dosing Guide

3 starting doses: 6 mg/kg administered monthly

6mg/kg dose

Start

6mg/kg dose

Month 1

6mg/kg dose

Month 2

Ongoing dosing: 6 mg/kg administered quarterly beginning one month after the last starting dose

6mg/kg dose

Month 3

No dose

Month 4

No dose

Month 5

6mg/kg dose

Month 6

Ongoing quarterly dosing continues past month 6

Download the Dosing Guide

3 starting doses: 6 mg/kg administered monthly

6mg/kg dose

Start

6mg/kg dose

Month 1

6mg/kg dose

Month 2

Ongoing dosing: 3 mg/kg administered monthly beginning one month after the last starting dose

3mg/kg dose

Month 3

3mg/kg dose

Month 4

3mg/kg dose

Month 5

3mg/kg dose

Month 6

Ongoing monthly dosing continues past month 6

Download the Dosing Guide

If your patient misses a dose
If a dose is delayed or missed, administer OXLUMO as soon as possible and resume prescribed regimen from the most recently administered dose.1

Image

OXLUMO Administration

  • Administered via subcutaneous injection by a healthcare professional1
    • Some patients may qualify to receive the injection at home from a healthcare professional, depending on their insurance coverage
  • No dose adjustment is necessary in patients with renal impairment, including kidney failure, or those on hemodialysis

For patients on hemodialysis, administer OXLUMO following hemodialysis if administered on dialysis days.

See full Prescribing Information for detailed steps on how to prepare and administer OXLUMO.

Show Me the Prescribing Information

Image

WANT TO SPEAK WITH AN OXLUMO REPRESENTATIVE?

Our representatives are available to provide detailed information about OXLUMO and how it may help your patients with PH1.

Let's Connect

Image
'

There’s more to learn about OXLUMO

When you sign up, we will keep you informed with updates and resources.

Sign Me Up

Image
Alnylam Assist™ Logo

Alnylam Assist® provides support services for patients throughout their treatment with OXLUMO.

Alnylam Assist® includes patient services in 4 key areas, including understanding insurance benefits and financial assistance options for eligible patients,* helping ensure access to therapy, and providing PH1 disease education.

Let's Get Started

Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.

1. OXLUMO [Package Insert]. Cambridge, MA. Alnylam Pharmaceuticals, Inc.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
The most common (≥20%) adverse reaction reported in patients treated with OXLUMO was injection site reaction. Injection site reactions included erythema, swelling, pain, hematoma, pruritus, and discoloration.

Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.

INDICATION

OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.